PacketFabric's Connectivity-as-a-Service Platform Expanding to London
Equinix LD6 International Business Exchange, the First Data Center Outside the U.S. Accessible on PacketFabric's Network, Marks Company's Expansion into Europe
CULVER CITY, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- PacketFabric announces the expansion of its highly scalable Connectivity-as-a-Service (CaaS) platform to the Equinix LD6 International Business Exchange(TM) (IBX®), a flagship facility of Equinix, Inc. (Nasdaq:EQIX) located at its London Slough data center campus. Equinix LD6 IBX is the first data center outside of the United States to be added to the PacketFabric network, beginning the company's expansion into Europe.
PacketFabric customers will be able to access the Equinix LD6 data center from any location on the PacketFabric network. As a highly scalable Connectivity-as-a-Service platform, PacketFabric, a member of the NantWorks ecosystem of companies, provides network connectivity on demand. Compared to legacy carriers, PacketFabric offers connectivity speeds from 1Gbps to multi-100Gbps, instantly available through an intuitive portal and API, reducing the sourcing and provisioning times of network services to minutes.
"It's always been PacketFabric's long-term vision to expand outside of the United States to better serve our customers with international interests," states Chad Milam, President and COO of PacketFabric. "We're excited to add Equinix's flagship LD6 data center to our fabric, as the start of our global expansion."
PacketFabric operates a multi-terabit U.S. footprint that includes more than 150 Points of Presence (PoPs) in 17 metro markets. PacketFabric has also created a dedicated cloud connectivity product, PacketCOR, which allows its customers to establish direct, secure connections to cloud service products, such as AWS, Azure ExpressRoute, and many more. By establishing a PoP at Equinix's LD6 data center, located at the hub of Europe's largest financial market, PacketFabric's customers seeking international connectivity options in London will be able to gain access to advanced networking solutions through its highly-scalable, automated Software-defined Networking (SDN) platform.
For more information about PacketFabric, visit www.packetfabric.com.
PacketFabric redefines how companies procure, consume, and manage their network connectivity services. Leveraging an innovative, entirely automated SDN-based network architecture and the latest in optical and packet switching technology, PacketFabric enables dynamic, real-time connectivity services between major carrier-neutral colocation facilities at terabit-scale. PacketFabric facilitates coast-to-coast connectivity between more than 150 premier colocation facilities across 17 U.S. markets, and enables simple, cost-effective, and scalable network deployment via its advanced Application Program Interface (API) and web-based portal. For more information, visit www.packetfabric.com or connect with PacketFabric on Twitter , LinkedIn and Facebook.
NantWorks, LLC, founded by renowned physician scientist and inventor of the first human nanoparticle chemotherapeutic agent Abraxane®, Dr. Patrick Soon-Shiong, is the umbrella organization for the following entities: NantHealth, NantMobileHealth, NantOmics, NantBio, NantCell, NantPharma, NantCapital and NantCloud. Fact-based and solution-driven, each of NantWorks' division entities operate at the nexus of innovation and infrastructure. The core mission of NantWorks is convergence and a systems approach to human biology: to develop and deliver a diverse range of technologies that accelerates innovation, broaden the scope of scientific discovery, enhance ground-breaking research, and improve healthcare treatment for those in need. NantWorks is building an integrated fact-based, genomically and proteomically-informed, personalized approach to the delivery of care and the development of next generation diagnostics and therapeutics for life threatening diseases such as Cancer, Infectious Diseases and Alzheimer's. For more information please visit www.nantworks.com and follow Dr. Soon-Shiong on Twitter at @DrPatSoonShiong.
iMiller Public Relations for PacketFabric
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c3bd1d15-7392-4feb-a415-229c47f85410
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PacketFabric via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
AMG Advanced Metallurgical Group N.V. Announces Weekly Share Repurchase Program Transaction Details19.7.2019 21:00:00 CEST | Press release
Amsterdam, 19 July 2019 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") reports the repurchases made under its share repurchase program announced on 8 April 2019 and effective from 9 April 2019. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period 15 July 2019 through 19 July 2019 can be found in the bottom half of the table below. Further detailed information regarding both the progress of the share repurchase program and the overall trades made on a daily basis can be accessed via the Investors section of the Company’s website, or clicking the following link: https://amg-nv.com/investors/share-buyback/ Share Repurchase Program Overall progress Share Repurchase Program: Total Repurchase Amount in Shares 2,915,630 Cumulative Repurchase Amount EUR 63,511,098 Cumulative Quantity Repurchased 2,534,054 Cumulative Average Repurchase Price EUR 25.06 Start Date 9 April
Ossur Hf : Össur acquires College Park Industries19.7.2019 17:00:00 CEST | Press release
Reykjavik, 19 July 2019 Össur has signed an agreement to acquire College Park Industries, a global provider of lower and upper limb prostheses and supporting services. College Park has over 140 employees and is headquartered in Detroit, USA. Total sales amounted to USD 22 million in 2018. College Park will largely remain independent and continue to diligently serve its customer base, while allowing the combined entity to achieve strategic efficiencies. Össur is committed to growing the College Park brand over the coming years both in the United States and international markets. Together, both companies will be well-positioned to enhance their offerings in both lower and upper limb prosthetics. With this acquisition, Össur hopes to support College Park’s focus on the lower active population and further strengthen its established presence in the upper limb arena. Mutual access to technology and products will enable a more comprehensive product and service offering to customers around the
Banks net position in the Riksbank19.7.2019 16:47:00 CEST | Press release
JUL 19, 2019 SEK MILLION LENDING BORROWING 277
Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for andre kvartal 201919.7.2019 14:43:00 CEST | Pressemelding
Hydros resultat for andre kvartal 2019 blir offentliggjort tirsdag 23. juli 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Eivind Kallevik. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til firstname.lastname@example.org. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å ringe: Norge +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sverige +46 (0)8 5033 6574 Brasil +55 11 3181 5427 Tyskland +49 (0)89 20303 5709 Kode: 3104804 Q&A / Telefonkonferanse Det blir holdt en telefonkonferans
Norsk Hydro: REMINDER: Invitation - Hydro’s second quarter results 201919.7.2019 14:43:00 CEST | Press release
Hydro's second quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Tuesday July 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Eivind Kallevik and can also be seen on web TV. To attend the presentation in Oslo, please register by sending a mail to email@example.com. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). Dial-in numbers for this conference call are: Norway +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sweden +46 (0)8 5033 6574 Brazil +55 11 3181 5427 Germany +49 (0)89 20303 5709 Confirmation Code: 3104804 Q&A
Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CEST | Pressemelding
STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have